What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Phosphatase Enzyme: Function, Mechanism, and Biological Roles

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Phosphatase Enzymes

What Is a Phosphatase?

A phosphatase enzyme is a hydrolase that removes phosphate groups from its substrates by catalyzing the cleavage of phosphate–ester or phosphate–anhydride bonds. The reaction consumes water and releases a free phosphate ion and a hydroxyl-bearing product. Phosphatases act on a wide range of substrates, including proteins, nucleotides, lipids, and small metabolites. In the context of molecular cell signaling, the most intensively studied phosphatases are those that dephosphorylate serine, threonine, and tyrosine residues on proteins.

The human genome encodes approximately 200 protein phosphatases, a number comparable to the roughly 500 protein kinases that catalyze the opposing phosphorylation reaction. This numerical disparity is misleading, however, because many phosphatases achieve substrate specificity through regulatory subunits and subcellular targeting rather than through one-to-one kinase–phosphatase pairing. Phosphatases are not merely "off switches" for kinase action; they are independently regulated enzymes that shape the amplitude, duration, and spatial distribution of phosphorylation signals.

Phosphatases are grouped into broad families based on substrate chemistry. Protein tyrosine phosphatases (PTPs) remove phosphate from phosphotyrosine residues. Serine/threonine phosphatases (STPs) act on phosphoserine and phosphothreonine. Dual-specificity phosphatases (DUSPs) can act on both tyrosine and serine/threonine residues. Lipid phosphatases, such as PTEN (phosphatase and tensin homolog), remove phosphate from phospholipid head groups rather than from protein residues. Each family uses a distinct catalytic strategy, which has important implications for inhibitor design and for understanding disease-associated mutations.

Phosphatases vs. Kinases

Kinases transfer the terminal phosphate group of ATP to a substrate, typically a hydroxyl group on a protein side chain, a lipid, or a sugar. Phosphatases reverse this reaction by hydrolyzing the phosphate–substrate bond. The two enzyme classes are often described as opposing forces, but this framing understates their cooperation. In a signaling pathway, the steady-state phosphorylation level of any substrate is determined by the ratio of kinase activity to phosphatase activity, not by the absolute activity of either enzyme alone. A kinase can phosphorylate a substrate rapidly, but if a phosphatase dephosphorylates it equally rapidly, the net signal remains low. Conversely, inhibition of a phosphatase can amplify a signal even when kinase activity is unchanged.

The catalytic mechanisms are fundamentally different. Kinases use ATP as a phosphoryl donor and typically require a divalent metal ion, usually Mg²⁺, to coordinate the ATP phosphates. Phosphatases use water as the phosphate acceptor and often employ metal ions, cysteine nucleophiles, or aspartic acid residues to activate the water molecule and stabilize the transition state. These mechanistic differences mean that a drug that inhibits a kinase will not inhibit a phosphatase, and vice versa. Understanding this distinction is essential for interpreting experiments that use kinase or phosphatase inhibitors and for appreciating why both enzyme classes are attractive but distinct drug targets.

Chemical Mechanism of Phosphate Removal

Catalytic Mechanism

The dephosphorylation reaction catalyzed by a phosphatase is a hydrolysis reaction. For a phosphoprotein substrate, the reaction is:

Protein–O–PO₃²⁻ + H₂O → Protein–OH + HPO₄²⁻

The reaction proceeds through a pentacoordinate phosphorus transition state in which the phosphate group is transiently bound to five oxygen atoms. The phosphatase must stabilize this transition state to lower the activation energy. Different phosphatase families achieve this stabilization in different ways.

Serine/threonine phosphatases, such as protein phosphatase 1 (PP1), protein phosphatase 2A (PP2A), and calcineurin (PP2B), use a binuclear metal center. Two metal ions, typically Mn²⁺, Fe²⁺, or Zn²⁺, are coordinated by histidine and aspartate residues at the active site. One metal ion activates a water molecule to generate a hydroxide ion, which attacks the phosphorus atom of the substrate. The second metal ion stabilizes the developing negative charge on the leaving group oxygen. The reaction proceeds in a single step without a covalent phosphoenzyme intermediate.

Protein tyrosine phosphatases use a completely different strategy. The active site contains a conserved cysteine residue within the signature motif HC(X)₅R (histidine, cysteine, five variable residues, arginine). The cysteine thiolate (Cys–S⁻) acts as a nucleophile and attacks the phosphorus atom, forming a covalent phosphocysteine intermediate. The conserved arginine positions the phosphate group and stabilizes the transition state. In the second step, a conserved aspartic acid activates a water molecule, which hydrolyzes the phosphocysteine intermediate and releases the phosphate. This two-step mechanism is faster for substrate binding but requires the cysteine to be maintained in a reduced state; oxidation of the cysteine to sulfenic acid inactivates the enzyme.

Dual-specificity phosphatases use a cysteine-based mechanism similar to the PTPs but have a shallower active site cleft, which allows them to accommodate the longer side chains of phosphoserine and phosphothreonine in addition to phosphotyrosine.

Metal Ions in Catalysis

Metal ions are essential for the catalytic activity of serine/threonine phosphatases and for some lipid phosphatases. The binuclear metal center in PP1, PP2A, and calcineurin is not merely structural; it participates directly in catalysis. The metal ions lower the pKa of the coordinated water molecule, enabling it to donate a proton and generate a nucleophilic hydroxide at physiological pH. Without the metals, the water molecule is too weakly nucleophilic to attack the phosphate group at a measurable rate.

The identity of the metal ions affects enzyme activity and inhibitor sensitivity. PP1 and PP2A can use Mn²⁺ or Fe²⁺, while calcineurin is activated by Ca²⁺–calmodulin and contains Fe³⁺ and Zn²⁺ at its active site. This metal dependence is exploited experimentally: chelating agents such as EDTA (ethylenediaminetetraacetic acid) and EGTA (ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid) inhibit metal-dependent phosphatases by sequestering the required ions. In a typical in vitro assay, a serine/threonine phosphatase reaction is performed in a buffer containing 50 mM Tris-HCl (pH 7.0), 0.1 mM MnCl₂, and 1 mM dithiothreitol to maintain the metal center and reduce any oxidized cysteine residues.

Classification of Phosphatases

Serine/Threonine Phosphatases

The serine/threonine phosphatases are divided into the phosphoprotein phosphatase (PPP) family and the metal-dependent protein phosphatase (PPM) family. The PPP family includes PP1, PP2A, PP2B (calcineurin), and PP4, PP5, and PP6. These enzymes share a conserved catalytic core of approximately 280 amino acids but differ in their regulatory subunits. PP1, for example, has a catalytic subunit that is essentially inactive on its own; it must bind to one of over 200 regulatory subunits to achieve substrate specificity and subcellular localization. PP2A is similarly regulated by a scaffolding A subunit and a variable B subunit, which determines the substrate selectivity of the holoenzyme.

The PPM family includes PP2C, which is structurally unrelated to the PPP family and requires Mg²⁺ or Mn²⁺ for activity. PP2C is monomeric and does not use regulatory subunits. It is involved in stress responses and in the negative regulation of p38 and JNK (c-Jun N-terminal kinase) MAP kinase pathways.

Tyrosine Phosphatases

The protein tyrosine phosphatase family is divided into classical PTPs, which are specific for phosphotyrosine, and dual-specificity phosphatases. Classical PTPs include receptor-like enzymes such as CD45, which is expressed on immune cells and regulates T-cell receptor signaling, and cytoplasmic enzymes such as PTP1B (protein tyrosine phosphatase 1B), which is a major negative regulator of insulin and leptin signaling. The classical PTPs contain a conserved catalytic domain of approximately 240 residues with the signature motif HC(X)₅R. The depth of the active site cleft is about 9 Å, which accommodates the long side chain of phosphotyrosine but excludes the shorter phosphoserine and phosphothreonine side chains.

Dual-Specificity Phosphatases

Dual-specificity phosphatases (DUSPs) can dephosphorylate both phosphotyrosine and phosphoserine/phosphothreonine. The most well-known members are the MAP kinase phosphatases (MKPs), such as DUSP1 (also called MKP-1), which dephosphorylate the threonine and tyrosine residues within the activation loop of MAP kinases. The active site of a DUSP is shallower than that of a classical PTP, allowing access to the shorter phosphoserine and phosphothreonine side chains. DUSPs also include the tumor suppressor PTEN, which dephosphorylates phosphatidylinositol 3,4,5-trisphosphate (PIP₃) at the 3-position of the inositol ring, and the RNA-binding protein VHR (vaccinia H1-related), which dephosphorylates ERK (extracellular signal-regulated kinase).

Lipid Phosphatases

Lipid phosphatases remove phosphate groups from phospholipids. PTEN is the most intensively studied lipid phosphatase. It removes the 3-phosphate from PIP₃, converting it to phosphatidylinositol 4,5-bisphosphate (PIP₂). This reaction directly opposes the action of phosphoinositide 3-kinase (PI3K), which generates PIP₃. By reducing PIP₃ levels, PTEN dampens the PI3K–AKT signaling pathway, which promotes cell survival, growth, and proliferation. Loss of PTEN function, through mutation, deletion, or promoter methylation, is one of the most common events in human cancer. SHIP (SH2-containing inositol 5-phosphatase) is another lipid phosphatase; it removes the 5-phosphate from PIP₃, generating phosphatidylinositol 3,4-bisphosphate.

Role in Cell Signaling Pathways

Phosphatases in MAPK Pathway

The mitogen-activated protein kinase (MAPK) cascade is a three-tiered kinase module that transmits extracellular signals to the nucleus. The cascade consists of a MAP kinase kinase kinase (MAPKKK), which phosphorylates and activates a MAP kinase kinase (MAPKK), which in turn phosphorylates and activates a MAP kinase (MAPK). The terminal MAPKs—ERK, JNK, and p38—are activated by dual phosphorylation on a threonine and a tyrosine residue within their activation loops.

The dual phosphorylation of MAPKs is reversed by MAP kinase phosphatases (MKPs), which are dual-specificity phosphatases. DUSP1/MKP-1, for example, dephosphorylates both the threonine and the tyrosine in the activation loop of p38 and JNK, thereby inactivating these kinases. The expression of DUSP1 is itself induced by the MAPK pathway, creating a negative feedback loop that limits the duration and amplitude of MAPK signaling. This feedback is critical for normal cell cycle progression; sustained ERK activation, which can occur when MKPs are downregulated, drives uncontrolled proliferation in some cancers.

The specificity of MKPs is determined by their subcellular localization and by docking interactions with their MAPK substrates. DUSP1 is nuclear, DUSP4 is nuclear, and DUSP6 is cytoplasmic. Each MKP binds to its target MAPK through a kinase-interaction motif (KIM), which is distinct from the catalytic domain. This docking interaction increases the local concentration of substrate and ensures that the correct MAPK is dephosphorylated.

Phosphatases in Insulin Signaling

Insulin signaling is initiated when insulin binds to the insulin receptor, a receptor tyrosine kinase. The activated receptor autophosphorylates on multiple tyrosine residues, which then recruit downstream signaling proteins such as IRS-1 (insulin receptor substrate 1). IRS-1 is phosphorylated on tyrosine residues, creating binding sites for PI3K, which generates PIP₃ and activates AKT. AKT phosphorylates numerous downstream targets that promote glucose uptake, glycogen synthesis, and protein synthesis.

PTP1B is a major negative regulator of this pathway. It dephosphorylates the insulin receptor and IRS-1, thereby terminating the signal. Mice lacking PTP1B are hypersensitive to insulin and resistant to diet-induced obesity, which has made PTP1B an attractive drug target for type 2 diabetes. However, developing selective PTP1B inhibitors has been challenging because the active site is highly conserved across the PTP family. The related phosphatase TCPTP (T-cell protein tyrosine phosphatase) also dephosphorylates the insulin receptor but is more important in the liver, whereas PTP1B is more important in muscle and adipose tissue.

The lipid phosphatase PTEN also regulates insulin signaling by dephosphorylating PIP₃. Reduced PTEN expression enhances insulin sensitivity, but it also increases the risk of cancer, illustrating the trade-off inherent in targeting phosphatases for therapeutic benefit.

Regulation of Phosphatase Activity

Phosphorylation and Oxidation

Phosphatases are themselves regulated by post-translational modifications. PP1 is inhibited by phosphorylation of its catalytic subunit at threonine 320 by cyclin-dependent kinase 1 (CDK1) during mitosis. PP2A is regulated by phosphorylation of its scaffolding subunit and by reversible methylation of its catalytic subunit at the C-terminal leucine residue. Methylation of PP2A's catalytic subunit promotes assembly of the holoenzyme and is required for full activity.

Oxidation is a particularly important regulatory mechanism for cysteine-based phosphatases. The active site cysteine of PTPs has a low pKa, which makes it a strong nucleophile at physiological pH but also renders it susceptible to oxidation by reactive oxygen species (ROS). Hydrogen peroxide, which is produced by growth factor receptors and by NADPH oxidases, oxidizes the catalytic cysteine to sulfenic acid (Cys–SOH), which inactivates the enzyme. This transient inactivation allows tyrosine phosphorylation signals to persist longer. The sulfenic acid can be reduced back to the thiol by cellular reductants such as glutathione or thioredoxin. This redox regulation is reversible and is now recognized as a physiological mechanism for amplifying receptor tyrosine kinase signaling.

Regulatory Subunits

Many serine/threonine phosphatases achieve specificity through regulatory subunits. PP1 is a particularly striking example. The catalytic subunit of PP1 (PP1c) is one of the most promiscuous phosphatases in the cell, but it is almost always found in complex with a regulatory subunit that directs it to specific substrates and subcellular locations. More than 200 PP1-binding proteins have been identified. These include the glycogen-targeting subunit GM, which localizes PP1 to glycogen particles where it dephosphorylates glycogen phosphorylase and glycogen synthase, and the myosin-targeting subunit MYPT1, which localizes PP1 to smooth muscle myosin and regulates muscle contraction.

PP2A is similarly regulated by its B subunits. The B55 subunit targets PP2A to substrates involved in cell cycle progression, while the B56 subunit targets it to substrates in the Wnt signaling pathway. The diversity of regulatory subunits vastly expands the functional repertoire of a small number of catalytic subunits and explains how a single phosphatase can participate in dozens of distinct signaling pathways.

Methods to Study Phosphatase Enzymes

Phosphatase Activity Assays

Phosphatase activity is commonly measured using chromogenic or fluorogenic substrates. For alkaline phosphatase, the standard substrate is p-nitrophenyl phosphate (pNPP), which is colorless but is converted to yellow p-nitrophenolate (absorbance maximum at 405 nm) upon dephosphorylation. A typical assay uses 1–10 mM pNPP in 100 mM diethanolamine buffer (pH 9.8) containing 0.5 mM MgCl₂, incubated at 37°C for 10–30 minutes. The reaction is stopped by adding NaOH to raise the pH and maximize the absorbance of the product.

For protein tyrosine phosphatases, a commonly used substrate is p-nitrophenyl phosphate as well, but the assay is performed at lower pH (around 5.5–7.0) because the cysteine-based catalytic mechanism requires the thiolate form of the active site cysteine. For serine/threonine phosphatases, radiolabeled phosphoproteins are often used. A typical assay uses ³²P-labeled phosphorylase a as a substrate for PP1 or PP2A. The reaction is carried out in 50 mM Tris-HCl (pH 7.0), 0.1 mM EDTA, 0.1% β-mercaptoethanol, and 1 mM MnCl₂, and the released ³²P-phosphate is separated from the protein by acid precipitation and counted by scintillation.

Use of Phosphatase Inhibitors

Phosphatase inhibitors are essential tools for studying the contribution of specific phosphatases to a signaling pathway. Okadaic acid is a potent inhibitor of PP1 and PP2A, but it inhibits PP2A at much lower concentrations (IC₅₀ ≈ 0.1–1 nM) than PP1 (IC₅₀ ≈ 10–15 nM). Calyculin A inhibits both PP1 and PP2A at similar concentrations. Cyclosporin A and FK506 inhibit calcineurin (PP2B) by forming complexes with immunophilins that bind to and block the calcineurin–calmodulin interface.

For tyrosine phosphatases, sodium orthovanadate is a broad-spectrum inhibitor that acts as a phosphate analog. It is typically used at concentrations of 0.1–1 mM in cell culture media. Pervanadate, formed by mixing vanadate with hydrogen peroxide, is a more potent inhibitor because it irreversibly oxidizes the active site cysteine. More selective inhibitors, such as the PTP1B inhibitor TCS-401, have been developed for research and therapeutic purposes.

Genetic and Proteomic Approaches

Genetic approaches include gene knockout, RNA interference (RNAi), and CRISPR-Cas9-mediated gene editing. These methods allow researchers to determine the phenotype associated with loss of a specific phosphatase. For example, knockout of PTEN in mice is embryonic lethal, whereas heterozygous knockout mice develop tumors in multiple tissues. Conditional knockouts, in which the phosphatase is deleted in a specific tissue or at a specific time, provide more detailed information about tissue-specific functions.

Phosphoproteomics is a powerful approach for identifying the substrates of a phosphatase. In a typical experiment, cells are treated with a phosphatase inhibitor or the phosphatase is knocked down, and the phosphoproteome is analyzed by mass spectrometry. This approach can identify hundreds of phosphorylation sites that change in abundance, providing a global view of phosphatase function. However, distinguishing direct substrates from indirect effects requires additional validation, such as in vitro dephosphorylation assays with purified proteins.

Phosphatases in Disease and Therapeutics

Phosphatases in Cancer

Phosphatases can act as tumor suppressors or oncogenes depending on the context. PTEN is a bona fide tumor suppressor; its loss is observed in a wide range of cancers, including glioblastoma, prostate cancer, and endometrial cancer. Loss of PTEN leads to elevated PIP₃ levels and constitutive activation of AKT, promoting cell survival and proliferation. The gene encoding PP2A is also considered a tumor suppressor; its activity is frequently reduced in cancer through mutations in the scaffolding or regulatory subunits or through overexpression of endogenous inhibitors such as CIP2A (cancerous inhibitor of PP2A).

Other phosphatases can promote cancer. SHP2 (SH2 domain-containing protein tyrosine phosphatase 2), encoded by the PTPN11 gene, is a positive regulator of the RAS–MAPK pathway. Gain-of-function mutations in PTPN11 cause Noonan syndrome and are found in juvenile myelomonocytic leukemia and other cancers. SHP2 inhibitors are currently in clinical development for cancers driven by the RAS–MAPK pathway.

Phosphatases as Drug Targets

The development of phosphatase inhibitors as drugs has been challenging but is progressing. The major obstacle is selectivity: the active sites of many phosphatases are highly conserved, making it difficult to design inhibitors that target one phosphatase without affecting others. However, several strategies have emerged. Allosteric inhibitors that bind outside the active site can achieve high selectivity. For example, SHP2 inhibitors such as SHP099 bind to a tunnel-like allosteric site and stabilize the autoinhibited conformation of the enzyme.

PTP1B inhibitors have been developed for the treatment of type 2 diabetes and obesity. Despite decades of effort, no PTP1B inhibitor has reached the market, largely due to poor oral bioavailability and selectivity issues. However, recent advances in fragment-based drug design and the identification of novel binding sites have renewed interest. Calcineurin inhibitors, cyclosporin A and FK506, are already in clinical use as immunosuppressants for organ transplantation. They work by inhibiting the calcium-dependent phosphatase calcineurin, which is required for T-cell activation.

Common Pitfalls and Misconceptions

Phosphatase vs. Phosphorylase

A common error is confusing phosphatases with phosphorylases. A phosphatase removes a phosphate group by hydrolysis, using water as the phosphate acceptor. A phosphorylase, in contrast, cleaves a glycosidic bond by adding phosphate to the substrate, using inorganic phosphate as the nucleophile. Glycogen phosphorylase, for example, cleaves glucose-1-phosphate from glycogen without using water. The products are different: a phosphatase produces a free phosphate ion and a hydroxyl group, whereas a phosphorylase produces a phosphorylated product. The two enzymes are mechanistically unrelated and should not be used interchangeably.

Dephosphorylation Does Not Always Mean Inactivation

Students often assume that phosphorylation activates a protein and dephosphorylation inactivates it. This is frequently true, but it is not a universal rule. Phosphorylation can either activate or inhibit a protein, depending on the site and the protein. For example, phosphorylation of glycogen synthase by glycogen synthase kinase 3 (GSK3) inactivates the enzyme, and dephosphorylation by PP1 activates it. In contrast, phosphorylation of the transcription factor CREB (cAMP response element-binding protein) at serine 133 activates it, and dephosphorylation inactivates it. The same kinase can even have opposite effects on different substrates. Therefore, the functional consequence of phosphorylation must be determined empirically for each substrate and each phosphorylation site.

Overlooking Phosphatase Specificity

Another misconception is that phosphatases are nonspecific "housekeeping" enzymes that simply reverse whatever kinases do. In reality, phosphatases are highly regulated and often highly specific. PP1 is targeted to specific substrates by its regulatory subunits, and the MKPs specifically dephosphorylate MAP kinases. The specificity is achieved not only by the catalytic domain but also by docking interactions, subcellular localization, and the timing of expression. A phosphatase that appears nonspecific in vitro may be highly specific in vivo because it is only expressed in certain cells or only localized to certain compartments.

Summary and Key Takeaways

Phosphatases are essential enzymes that remove phosphate groups from proteins, lipids, and small molecules. They oppose the action of kinases but are not simple antagonists; they are independently regulated enzymes that shape signaling dynamics. The major families—serine/threonine phosphatases, tyrosine phosphatases, dual-specificity phosphatases, and lipid phosphatases—use distinct catalytic mechanisms and are regulated by distinct mechanisms. Phosphatases are involved in virtually every signaling pathway, and their dysfunction contributes to cancer, diabetes, immune disorders, and neurological diseases. Understanding phosphatases is therefore essential for understanding cell signaling and for developing targeted therapies.

Frequently Asked Questions

Is phosphatase an enzyme?

Yes, a phosphatase is an enzyme. It belongs to the hydrolase class of enzymes (EC 3.1.3.x) and catalyzes the removal of phosphate groups from substrates by hydrolysis. Phosphatases are proteins, and like all enzymes, they accelerate a specific chemical reaction without being consumed in the process.

What is the function of phosphatase enzymes?

The primary function of phosphatases is to remove phosphate groups from substrates. This reaction regulates the activity, localization, and interactions of proteins and lipids. In cell signaling, phosphatases counteract the action of kinases and thereby control the duration and amplitude of signaling events. Phosphatases also participate in metabolic processes, such as glycogen metabolism, and in the recycling of phosphate from nucleotides and other phosphorylated metabolites.

How do phosphatases differ from kinases?

Kinases transfer a phosphate group from ATP to a substrate, whereas phosphatases remove a phosphate group from a substrate by adding water. Kinases require ATP and typically Mg²⁺, while phosphatases use water and often require metal ions such as Mn²⁺, Fe²⁺, or Zn²⁺. The two enzyme classes are functionally opposed but often cooperate to produce precise signaling dynamics.

What are the types of phosphatases?

Phosphatases are classified by substrate specificity. Serine/threonine phosphatases (PP1, PP2A, PP2B, PP2C) act on phosphoserine and phosphothreonine. Tyrosine phosphatases (PTP1B, CD45, SHP2) act on phosphotyrosine. Dual-specificity phosphatases (MKPs, PTEN) act on both tyrosine and serine/threonine residues or on lipid substrates. Lipid phosphatases (PTEN, SHIP) remove phosphate from phospholipids.

Why are phosphatases important in cell signaling?

Phosphatases are critical because they determine the steady-state level of protein phosphorylation. They terminate signals, create negative feedback loops, and enable cells to respond to repeated stimuli. Without phosphatases, phosphorylation signals would persist indefinitely, leading to uncontrolled proliferation, inappropriate gene expression, and metabolic dysregulation.

Can phosphatases be inhibited?

Yes, phosphatases can be inhibited by small molecules, peptides, and proteins. Okadaic acid inhibits PP1 and PP2A, cyclosporin A inhibits calcineurin, and sodium orthovanadate inhibits tyrosine phosphatases. Phosphatase inhibitors are used both as research tools and as therapeutic agents. For example, cyclosporin A is used clinically as an immunosuppressant.

What happens if phosphatases are mutated?

Mutations in phosphatases can cause disease. Loss-of-function mutations in PTEN cause cancer predisposition syndromes such as Cowden syndrome. Gain-of-function mutations in SHP2 cause Noonan syndrome and contribute to leukemia. Mutations in the myotubularin family of lipid phosphatases cause X-linked centronuclear myopathy. The specific phenotype depends on the phosphatase, the mutation, and the affected tissue.

Key Takeaways

Phosphatases are hydrolase enzymes that remove phosphate groups from proteins, lipids, and metabolites by hydrolysis.
They oppose kinases but are independently regulated and often highly specific, achieving selectivity through regulatory subunits and subcellular targeting.
The major families are serine/threonine phosphatases, tyrosine phosphatases, dual-specificity phosphatases, and lipid phosphatases, each with distinct catalytic mechanisms.
Phosphatases regulate essential signaling pathways including the MAPK cascade and insulin signaling, and they are critical for normal development and homeostasis.
Phosphatase dysfunction contributes to cancer, diabetes, immune disorders, and neurological diseases, making them important drug targets.
Common misconceptions include confusing phosphatases with phosphorylases and assuming dephosphorylation always inactivates a protein.
Phosphatases are studied using activity assays, selective inhibitors, genetic manipulation, and phosphoproteomics.